KITE-753 Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for KITE-753 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hematologic Neoplasms. Most recent publication: Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2., J Hematol Oncol, 2026.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.Muñoz J, Locke FL, Reagan PM, et al. · J Hematol Oncol · 2026
Publications by year
2026–2026: 1 publications.
2026
1
Publications by indication
Hematologic Neoplasms (1)
- Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
Publications by journal
- J Hematol Oncol1 paper
All KITE-753 publications (1)
2026 (1 paper)
- Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.Muñoz J, Locke FL, Reagan PM, et al. · J Hematol Oncol · 2026 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 02 Jun 2026 17:35:55 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).